Literature DB >> 19165133

Pertussis vaccine: a critique.

John B Robbins1, Rachel Schneerson, Jerry M Keith, Mark A Miller, Joanna Kubler-Kielb, Birger Trollfors.   

Abstract

A critical level of serum IgG pertussis toxin antibody is both essential and sufficient to confer individual and herd immunity to pertussis. Monocomponent pertussis toxoid conferred such immunity in Sweden and in Denmark. We refute the notion that filamentous hemagglutinin, pertactin, and fimbriae add to the immunity conferred by pertussis toxoid and describe the artifact created when efficacy is estimated for multicomponent pertussis vaccines. Lastly, the genetically-inactivated mutant pertussis toxoid is safer, more immunogenic, and should be more effective than the current chemically-inactivated pertussis toxin.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19165133      PMCID： PMC3128455          DOI： 10.1097/INF.0b013e31818a8958

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  61 in total

1.  Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.

Authors:  Andrew L Baughman; Kristine M Bisgard; Kathryn M Edwards; Dalya Guris; Michael D Decker; Kathy Holland; Bruce D Meade; Freyja Lynn
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

2.  Summary of notifiable diseases--United States, 2004.

Authors:  Ruth Ann Jajosky; Patsy A Hall; Deborah A Adams; Felicia J Dawkins; Pearl Sharp; Willie J Anderson; J Javier Aponte; Gerald F Jones; David A Nitschke; Carol A Worsham; Nelson Adekoya; Timothy Doyle
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-06-16       Impact factor: 17.586

3.  Efficacy of whole-cell pertussis vaccine in preschool children in the United States.

Authors:  I M Onorato; S G Wassilak; B Meade
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

4.  Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions.

Authors:  W C Blackwelder; J Storsaeter; P Olin; H O Hallander
Journal:  Am J Dis Child       Date:  1991-11

Review 5.  A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned.

Authors:  R Schneerson; J B Robbins; J Taranger; T Lagergård; B Trollfors
Journal:  Lancet       Date:  1996-11-09       Impact factor: 79.321

Review 6.  Pertussis immunisation in adolescents and adults--Bordetella pertussis epidemiology should guide vaccination recommendations.

Authors:  Ulrich Heininger; James D Cherry
Journal:  Expert Opin Biol Ther       Date:  2006-07       Impact factor: 4.388

7.  Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children.

Authors:  C H Wirsing von König; D Gounis; S Laukamp; H Bogaerts; H J Schmitt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-05       Impact factor: 3.267

8.  Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons.

Authors:  J Taranger; B Trollfors; E Bergfors; N Knutsson; V Sundh; T Lagergård; L Lind-Brandberg; G Zackrisson; J White; H Cicirello; J Fusco; J B Robbins
Journal:  Clin Infect Dis       Date:  2001-08-22       Impact factor: 9.079

9.  Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses.

Authors:  E Bergfors; B Trollfors; J Taranger; T Lagergård; V Sundh; G Zackrisson
Journal:  Int J Infect Dis       Date:  1999       Impact factor: 3.623

10.  Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal.

Authors:  F Simondon; I Iteman; M P Preziosi; A Yam; N Guiso
Journal:  Clin Diagn Lab Immunol       Date:  1998-03
View more
  12 in total

Review 1.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

2.  Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.

Authors:  Jamie N Sutherland; Christine Chang; Sandra M Yoder; Michael T Rock; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

3.  Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine.

Authors:  Olajumoke O Fadugba; Li Wang; Qingxia Chen; Natasha B Halasa
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

4.  Toward a new vaccine for pertussis.

Authors:  John B Robbins; Rachel Schneerson; Joanna Kubler-Kielb; Jerry M Keith; Birger Trollfors; Evgeny Vinogradov; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-20       Impact factor: 11.205

Review 5.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

Review 6.  Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools.

Authors:  Nicholas H Carbonetti
Journal:  Future Microbiol       Date:  2010-03       Impact factor: 3.165

7.  Bordetella pertussis infection in a child with completed primary immunization: A case report.

Authors:  Ananda Giri Shankar; Alan Lee; Harish Reddy; Martin Seymour
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

8.  Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Teresa Lagergård; Ariel Ginzberg; Jerry D King; Andrew Preston; Duncan J Maskell; Vince Pozsgay; Jerry M Keith; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

9.  Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking.

Authors:  Edith Acquaye-Seedah; Yimin Huang; Jamie N Sutherland; Andrea M DiVenere; Jennifer A Maynard
Journal:  Cell Microbiol       Date:  2018-09-23       Impact factor: 3.715

10.  A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough.

Authors:  Annalee W Nguyen; Ellen K Wagner; Joshua R Laber; Laura L Goodfield; William E Smallridge; Eric T Harvill; James F Papin; Roman F Wolf; Eduardo A Padlan; Andy Bristol; Michael Kaleko; Jennifer A Maynard
Journal:  Sci Transl Med       Date:  2015-12-02       Impact factor: 17.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.